Target intelligence / Profile preview

Solute carrier family 35 member B1 (SLC35B1)

Target
SLC35B1
Molecular classification
Transporter (specifically, ATP/ADP exchanger in the endoplasmic reticulum membrane), Solute carrier (SLC) family protein
01

Overview

Solute carrier family 35 member B1 (SLC35B1) is a membrane transporter protein localized to the endoplasmic reticulum (ER) that mediates the strict exchange of ATP and ADP across the ER membrane. SLC35B1 is essential for maintaining an intraluminal supply of ATP, fueling protein folding, quality control, and trafficking within the ER. The protein operates by a distinctive antiport mechanism, exchanging cytosolic ATP for luminal ADP, and its function is structurally distinct from canonical nucleotide sugar transporters; it does not bind nucleotide sugars but specifically mediates ATP/ADP exchange. SLC35B1 is evolutionarily conserved, and loss of its function leads to decreased ER ATP levels, impaired chaperone activity (e.g., reduced BiP function), and reduced cell growth, underscoring its fundamental role in cell biology. Dysregulation or dysfunction of SLC35B1 has been implicated or suggested in diseases involving ER stress, such as type 2 diabetes, cancer, and neurodegenerative disorders. Current research aims to identify small molecules that modulate SLC35B1 activity, which could offer new avenues for therapeutic intervention in ER stress-related diseases.

Other names
AXERUGTREL1Endoplasmic reticulum ATP/ADP translocaseATP/ADP exchanger ERUDP-galactose transporter-related protein 1ATP/ADP exchanger in the ER membrane
02

Biological functions

ATP transport into the endoplasmic reticulum (ER)ADP export from ER (strict antiport mechanism)Maintenance of ER homeostasis through ATP supplySupports ER-dependent protein folding, post-translational modification, and quality controlRegulates unfolded protein responseCritical for energy metabolism in the ERHousekeeping role essential for cell growth and viability
03

Disease associations

ER stress and proteostasis disorders (dysregulation implicated or potentially implicated in disease)CancerNeurodegenerative diseaseMetabolic disorders (e.g., type 2 diabetes)Other diseases linked to ER dysfunction and stress
04

Safety considerations

Potential risk of disturbing cellular energy homeostasis if SLC35B1 function is modulated, leading to ER stress and downstream effects on cell viabilityEssential housekeeping gene—systemic inhibition could impair overall cell survival and protein homeostasisTherapeutic challenges in selectively targeting SLC35B1 without affecting normal cellular functions

Beyond the preview

Go deeper on Solute carrier family 35 member B1 (SLC35B1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 35 member B1 (SLC35B1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call